EP4720275A2 - Impfstoff für katzen zur blockierung der toxoplasma-oozysten-ablösung und -übertragung - Google Patents

Impfstoff für katzen zur blockierung der toxoplasma-oozysten-ablösung und -übertragung

Info

Publication number
EP4720275A2
EP4720275A2 EP24737579.3A EP24737579A EP4720275A2 EP 4720275 A2 EP4720275 A2 EP 4720275A2 EP 24737579 A EP24737579 A EP 24737579A EP 4720275 A2 EP4720275 A2 EP 4720275A2
Authority
EP
European Patent Office
Prior art keywords
parasite
ift88
toxoplasma gondii
gondii
srs15b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24737579.3A
Other languages
English (en)
French (fr)
Inventor
Michael E. GRIGG
Viviana PSZENNY
Aline SARDINHA DA SILVA
Jitender P. Dubey
Julius LUKES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biologicke Centrum Av Cr V V I
US Department of Agriculture USDA
US Department of Health and Human Services
Original Assignee
Biologicke Centrum Av Cr V V I
US Department of Agriculture USDA
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biologicke Centrum Av Cr V V I, US Department of Agriculture USDA, US Department of Health and Human Services filed Critical Biologicke Centrum Av Cr V V I
Publication of EP4720275A2 publication Critical patent/EP4720275A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24737579.3A 2023-06-02 2024-06-03 Impfstoff für katzen zur blockierung der toxoplasma-oozysten-ablösung und -übertragung Pending EP4720275A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363470773P 2023-06-02 2023-06-02
PCT/US2024/032292 WO2024250024A2 (en) 2023-06-02 2024-06-03 Vaccine for cats to block toxoplasma oocyst shedding and transmission

Publications (1)

Publication Number Publication Date
EP4720275A2 true EP4720275A2 (de) 2026-04-08

Family

ID=91758778

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24737579.3A Pending EP4720275A2 (de) 2023-06-02 2024-06-03 Impfstoff für katzen zur blockierung der toxoplasma-oozysten-ablösung und -übertragung

Country Status (2)

Country Link
EP (1) EP4720275A2 (de)
WO (1) WO2024250024A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120290323A (zh) * 2025-06-13 2025-07-11 江西农业大学 一种Tgsrs51基因缺失的弓形虫减毒虫株及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149197A1 (en) * 1994-06-17 1995-12-18 Irene Popiel Production of an efficacious toxoplasma gondii bradyzoite vaccine in tissue culture
US11945845B2 (en) * 2019-05-31 2024-04-02 Whitehead Institute For Biomedical Research Compositions and methods for regulation of chronic toxoplasma infection

Also Published As

Publication number Publication date
WO2024250024A2 (en) 2024-12-05
WO2024250024A3 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
AU2004286879B2 (en) Protozoan strains of reduced virulence and use thereof
Yan et al. Stable transfection of Eimeria tenella: constitutive expression of the YFP-YFP molecule throughout the life cycle
US8142771B2 (en) Use of coccidian
US9931396B2 (en) Koi herpesvirus vaccine
KR102157911B1 (ko) 마이코플라스마 히오뉴모니아를 형질전환하기 위한 벡터, 형질전환된 ｍ. 히오뉴모니아 균주, 및 그것의 용도
TW200924792A (en) A recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3) and a vaccine for the prevention of a disease caused by KHV/CyHV-3 in Cyorinus carpio carpio or Cyprinus carpio koi
US7351527B2 (en) Immunizing fish against viral infection
Ito et al. Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein
EP4720275A2 (de) Impfstoff für katzen zur blockierung der toxoplasma-oozysten-ablösung und -übertragung
US9585949B2 (en) Use of attenuated strains of parasites for the prevention or treatment of pathologies associates with an apicomplexan
Aravind et al. Protective effects of recombinant glycoprotein D based prime boost approach against duck enteritis virus in mice model
Yoon et al. Differential segregation of protective immunity by encoded antigen in DNA vaccine against pseudorabies virus
Padilla et al. Vaccine development for Chagas disease
EP2601211B1 (de) Impfstoff
US20210139883A1 (en) New attenuated strains of apicomplexa and their use as antigen vectors for the prevention of infectious diseases
WO2013113865A1 (en) Eimeria vector vaccine for campylobacter jejuni
KR101484605B1 (ko) Ｂｅｉ로 불활화된 일본뇌염 바이러스 ｋｖ1899주 항원 및 돼지의 ｇｍ－ｃｓｆ 재조합 단백질을 포함하는 일본뇌염 불활화 백신 조성물
Largo de la Torre Evaluation of the safety and efficacy of an inactivated vaccine prototype in standardized mouse and piglet models of toxoplasmosis
Baloglu Applicability of vaccinia virus as cloning and expression vector for bacterial genes: mice immune responses to vaccinia virus expressing Brucella abortus and Listeria monocytogenes antigens
CN120624205A (zh) 重组弓形虫虫株、构建方法及其应用
Kondiah Development of a DNA vaccine for the prevention of Psittacine beak and feather disease
CN121379821A (zh) 一种弓形虫RHΔrop64弱毒疫苗株及其构建方法与应用
AU2019271310A1 (en) Parasite vaccine
Xun et al. Pathology and Hygiene
HK1069532A (en) Attenuated live neospora vaccine

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR